Elicio Therapeutics Moves into Boston’s Seaport District and Provides Update on Programs
The Company has moved from Cambridge, MA to a new, larger space in the Seaport…
News
Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions
Study conducted with Tufts Medical Center represents a breakthrough showing that Microdose Array Print (MAP™)…
Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)…
Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference
MIAMI, March 15, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical…
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
– Dr. Dias is a biotech and pharma industry executive with more than 20 years…
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
Ovid executing on its strategy to build a leading epilepsy pipeline OV329 expected to enter…
INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 – International Conference on Alzheimer’s and Parkinson’s Diseases
Conference Provides First Exposure of EU and UK AD Experts to INmune Bio’s Approach of…
Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers
NCI achieves the enrollment objective of thirty patients in the checkpoint inhibitor refractory arm of…
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time
ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the…
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated…
Surface Oncology Appoints Theresa Boni as General Counsel
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
iSpecimen to Participate in Maxim’s 2022 Virtual Growth Conference on March 28-30, 2022
LEXINGTON, Mass., March 15, 2022 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the…
Acerus Reports Fourth Quarter and Full Year 2021 Financial Results
TORONTO, March 15, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:…
Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to…
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary…
Burning Rock to Release MRD Clinical Data on NSCLC and CRC at the Upcoming American Association for Cancer Research Annual Meeting
GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the…
Kamada Issues 2022 CEO Letter to Shareholders
REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a…
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Data readouts from multiple clinical trials expected during the next 6 to 12 months Strong…
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results
Revenues Grew 40% for the Fourth Quarter and 42% for Full Year 20212022 Guidance Reaffirmed…